[ad_1]
One of the most promising vaccines for Covid-19, developed by the University of Oxford in association with AstraZeneca, has produced a “Strong immune response” in people over 55, the Financial Times advances this Monday. Vaccines may be available to risk groups in January 2021 in the UK, the newspaper adds.
Studies have shown that the vaccine induces two forms of immunity in people over 55 years of age for at least 56 days, generating antibodies and T lymphocytes, which trigger and increase immunity in response to viral infections. Another study with similar conclusions had also been published in July, but the age group of the participants was between 18 and 55 years.
THEIR “A promising sign”According to Jonathan Ball, professor of virology at the University of Nottingham, once the immune system weakens with age and makes it difficult to develop a vaccine that induces a positive response against the new coronavirus in people over 55 years of age.
Still, Ball notes that the studies for the third phase are not finished. It should also be noted that positive immunogenicity tests, such as this one, They are not a guarantee that the vaccine is completely safe for people over 55 years of age. – this will only be known when the full test data is published.
Official British government source also heard by the Financial Times is optimistic about the vaccination of priority groups, such as health professionals, early January 2021, although there may be setbacks in the middle that lead to its postponement.
Still, Patrick Vallence, one of the British government’s scientific advisers in response to the pandemic, told a news conference last Thursday that while vaccine development is progressing, he only hoped that the broader use of the vaccine was only available in spring of next year.
Studies of the Oxford vaccine in collaboration with AstraZeneca were suspended a month ago after a possible serious and unexpected adverse reaction was detected in one of the volunteers who received the vaccine.
Vaccine tests are suspended. What is already known and what remains to be known
